NDAORALFOR SUSPENSIONPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
RELYVRIO (sodium phenylbutyrate; taurursodiol) by Amylyx Pharmaceuticals is clinical pharmacology sodium phenylbutyrate is a pro-drug and is rapidly metabolized to phenylacetate. Approved for all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life), late-onset disease (partial enzymatic deficiency and 1 more indications. First approved in 2022.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELYVRIO is an oral suspension combining sodium phenylbutyrate and taurursodiol, approved in September 2022 for urea cycle disorder (UCD) management in both neonatal-onset and late-onset disease presentations. Sodium phenylbutyrate acts as a pro-drug that metabolizes to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine—an alternate nitrogen waste excretion pathway comparable to urea on a molar basis. The fixed-dose combination represents an advancement over monotherapy approaches, addressing a rare but critical metabolic disease affecting nitrogen metabolism.
$0.2BPart D
14.2 years to LOEMechanism of Action
CLINICAL PHARMACOLOGY Sodium phenylbutyrate is a pro-drug and is rapidly metabolized to phenylacetate. Phenylacetate is a metabolically active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine. Phenylacetylglutamine then is excreted by the kidneys. On a molar…
Worked on RELYVRIO at Amylyx Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.